Asthma prescribing trends, inhaler adherence and outcomes: a Real-World Data analysis of a multi-ethnic Asian Asthma population

被引:1
|
作者
Toh, Ming Ren [1 ,2 ]
Ng, Gerald Xuan Zhong [1 ]
Goel, Ishita [3 ]
Lam, Shao Wei [4 ]
Wu, Jun Tian [4 ]
Lee, Chun Fan [1 ]
Ong, Marcus Eng Hock [1 ]
Matchar, David Bruce [1 ,5 ]
Tan, Ngiap Chuan [6 ]
Loo, Chian Min [1 ,2 ]
Koh, Mariko Siyue [1 ,2 ]
机构
[1] Duke NUS Med Sch, Singapore, Singapore
[2] Singapore Gen Hosp, Dept Resp & Crit Care Med, Singapore, Singapore
[3] Nanyang Technol Univ, Sch Phys & Math Sci, Singapore, Singapore
[4] Duke NUS Med Sch, Hlth Serv Res, Singapore, Singapore
[5] Duke Univ, Dept Internal Med, Med Sch, Durham, NC USA
[6] SingHealth Polyclin, Singapore, Singapore
关键词
OBSTRUCTIVE PULMONARY-DISEASE; MEDICATION ADHERENCE; BUDESONIDE-FORMOTEROL; HEALTH OUTCOMES; ADULT PATIENTS; CARE; CORTICOSTEROIDS; NONADHERENCE; COSTS; EXACERBATIONS;
D O I
10.1038/s41533-024-00391-w
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Inhaled corticosteroid (ICS) is the mainstay therapy for asthma, but general adherence is low. There is a paucity of real-world inhaler prescribing and adherence data from Asia and at the population level. To address these gaps, we performed a real-world data analysis of inhaler prescribing pattern and adherence in a multi-ethnic Asian asthma cohort and evaluated the association with asthma outcomes. We performed a retrospective analysis of adult asthma patients (aged >= 18 years) treated in the primary and specialist care settings in Singapore between 2015 to 2019. Medication adherence was measured using the medication possession ratio (MPR), and categorised into good adherence (MPR 0.75-1.2), poor adherence (MPR 0.75) or medication oversupply (MPR > 1.2). All statistical analyses were performed using R Studio. 8023 patients, mean age 57 years, were evaluated between 2015 and 2019. Most patients were receiving primary care (70.4%) and on GINA step 1-3 therapies (78.2%). ICS-long-acting beta-2 agonist (ICS-LABA) users increased over the years especially in the primary care, from 33% to 52%. Correspondingly, inpatient admission and ED visit rates decreased over the years. Between 2015 and 2019, the proportion of patients with poor adherence decreased from 12.8% to 10.5% (for ICS) and from 30.0% to 26.8% (for ICS-LABA) respectively. Factors associated with poor adherence included minority ethnic groups (Odds ratio of MPR 0.75-1.2: 0.73-0.93; compared to Chinese), presence of COPD (OR 0.75, 95% CI 0.59-0.96) and GINA step 4 treatment ladder (OR 0.71, 95% CI 0.61-0.85). Factors associated with good adherence were male gender (OR 1.14, 95% CI 1.01-1.28), single site of care (OR 1.22 for primary care and OR 1.76 for specialist care), GINA step 2 treatment ladder (OR 1.28, 95% CI 1.08-1.50). Good adherence was also associated with less frequent inpatient admission (OR 0.91, 95% CI 0.84-0.98), greater SABA overdispensing (OR 1.66, 95% CI 1.47-1.87) and oral corticosteroids use (OR 1.10, 95% CI 1.05-1.14). Inhaled corticosteroid (ICS) adherence has improved generally, however, poor adherence was observed for patients receiving asthma care in both primary and specialist care, and those from the minority ethnicities.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] VALIDITY AND RELIABILITY OF THE MORISKY SCALE FOR ADHERENCE TO GOUT THERAPY IN A MULTI-ETHNIC ASIAN POPULATION
    Tan, C. S. L.
    Teng, G. G.
    Chong, K. J.
    Lee, P. T.
    Cheung, P. P.
    Lim, A. Y. N.
    Wee, H. L.
    Santosa, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 1273 - 1273
  • [32] Trends in colorectal cancer, obesity, diet and population risk factors in a multi-ethnic Asian population
    Fernandes, Mark L.
    Chan, Yiong Huak
    Yeoh, Khay Guan
    GASTROENTEROLOGY, 2006, 130 (04) : A615 - A615
  • [33] Real-world data to measure and improve quality of asthma care
    Tang, Wern Ee
    Abisheganaden, John
    ANNALS ACADEMY OF MEDICINE SINGAPORE, 2023, 52 (10) : 491 - 492
  • [34] Real-World Data on Tezepelumab in Patients With Severe Asthma in Germany
    Biener, Leonie
    Muemmler, Carlo
    Hinze, Christopher Alexander
    Suhling, Hendrik
    Korn, Stephanie
    Fisser, Christoph
    Biener, Arne
    Pizarro, Carmen
    Lenoir, Alexandra
    Hackl, Caroline
    Skowasch, Dirk
    Milger, Katrin
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2024, 12 (09):
  • [35] THREE METHODS FOR DEFINING ASTHMA EXACERBATIONS IN REAL-WORLD DATA
    Bogart, M.
    Packnett, E.
    Manjelievskaia, J.
    Hahn, B.
    Ortega, H.
    Bell, C.
    Llanos, J. P.
    VALUE IN HEALTH, 2019, 22 : S359 - S359
  • [36] Complications and Outcomes of Primary Phacotrabeculectomy with Mitomycin C in a Multi-Ethnic Asian Population
    Chen, David Z.
    Koh, Victor
    Sng, Chelvin
    Aquino, Maria C.
    Chew, Paul
    PLOS ONE, 2015, 10 (03):
  • [37] Establishing the relationship of inhaler satisfaction, treatment adherence, and patient outcomes: a prospective, real-world, cross-sectional survey of US adult asthma patients and physicians
    Price, David
    Harrow, Brooke
    Small, Mark
    Pike, James
    Higgins, Victoria
    WORLD ALLERGY ORGANIZATION JOURNAL, 2015, 8
  • [38] Aflibercept for treatment-naive diabetic macula oedema in a multi-ethnic population: Real-world outcomes from North West London
    Dinah, Christiana
    Ghulakhszian, Arevik
    Sim, Sing Yue
    Minocha, Amal
    Nokhostin, Soroush
    Posner, Esther
    Cheong-Lee, Richard
    George, Sheena
    PLOS ONE, 2021, 16 (02):
  • [39] REAL-WORLD ADHERENCE TO SINGLE-INHALER FLUTICASONE FUROATE/UMECLIDINIUM/VILANTEROL VERSUS MULTIPLE-INHALER TRIPLE THERAPY AMONG ASTHMA PATIENTS IN THE US
    Averell, C.
    Germain, G.
    Laliberte, F.
    MacKnight, S.
    Jung, Y.
    Duh, M. S.
    Abbott, C.
    VALUE IN HEALTH, 2021, 24 : S13 - S13
  • [40] Longitudinal Outcomes of Severe Asthma: Real-World Evidence of Multidimensional Analyses
    Lee, Youngsoo
    Park, Youjin
    Kim, Chungsoo
    Lee, Eunyoung
    Lee, Hyun Young
    Woo, Seong-Dae
    You, Seng Chan
    Park, Rae Woong
    Park, Hae-Sim
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2021, 9 (03): : 1285 - +